Xiang Dong Tan
Vorsitzender bei Beijing Yingrebao Investments
Aktive Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Liren Tang | M | - |
Welichem Biotech, Inc.
 Welichem Biotech, Inc. Pharmaceuticals: MajorHealth Technology Welichem Biotech, Inc. operates as a drug discovery and early stage drug development company focusing on novel therapeutics for autoimmune, inflammatory diseases and cancers. The firm's focus has been on research and development of its novel anti-inflammatory drug candidate, WBI-1001 and its derivatives, and its anticancer drug candidate, WBI-2100 and its derivatives. The company was founded on November 1, 2004 and is headquartered in Burnaby, Canada. | 15 Jahre |
| Carolyn Anderson Short | F | 59 |
Himalaya Therapeutics
 Himalaya Therapeutics Medical/Nursing ServicesHealth Services Himalaya Therapeutics is a Caymanian clinical-stage biotechnology company that is advancing its pipeline of novel monoclonal antibody and other protein therapeutic product candidates through clinical trials. The company is based in George Town, Cayman Islands, with operations in Taiwan and China. The company's product candidates have been developed using cab technology, which is protected by more than 500 issued and pending patents. Himalaya has two cab programs currently in phase 2 clinical testing in Taiwan\: BA3011, a novel conditionally active AXL-targeted antibody-drug conjugate (CAB-AXL-ADC), and BA3021, a novel conditionally active ROR2-targeted antibody-drug conjugate (CAB-ROR2-ADC). Himalaya has a co-development and collaboration agreement for an investigational CAB CTLA-4 antibody, BA3071, with BeiGene Ltd. for its development, manufacturing, and commercialization in Greater China. The company was founded by Carolyn Anderson Short and Jay M. Short, and the CEO is Brian Zhang. | - |
| Jay Short | M | 66 |
Himalaya Therapeutics
Himalaya Therapeutics Medical/Nursing ServicesHealth Services Himalaya Therapeutics is a Caymanian clinical-stage biotechnology company that is advancing its pipeline of novel monoclonal antibody and other protein therapeutic product candidates through clinical trials. The company is based in George Town, Cayman Islands, with operations in Taiwan and China. The company's product candidates have been developed using cab technology, which is protected by more than 500 issued and pending patents. Himalaya has two cab programs currently in phase 2 clinical testing in Taiwan\: BA3011, a novel conditionally active AXL-targeted antibody-drug conjugate (CAB-AXL-ADC), and BA3021, a novel conditionally active ROR2-targeted antibody-drug conjugate (CAB-ROR2-ADC). Himalaya has a co-development and collaboration agreement for an investigational CAB CTLA-4 antibody, BA3071, with BeiGene Ltd. for its development, manufacturing, and commercialization in Greater China. The company was founded by Carolyn Anderson Short and Jay M. Short, and the CEO is Brian Zhang. | - |
| Tong Hui Liu | M | 61 | 8 Jahre | |
| Kit Kuen Yau | F | 56 | 7 Jahre | |
| Lawrence Steinman | M | 76 |
Himalaya Therapeutics
Himalaya Therapeutics Medical/Nursing ServicesHealth Services Himalaya Therapeutics is a Caymanian clinical-stage biotechnology company that is advancing its pipeline of novel monoclonal antibody and other protein therapeutic product candidates through clinical trials. The company is based in George Town, Cayman Islands, with operations in Taiwan and China. The company's product candidates have been developed using cab technology, which is protected by more than 500 issued and pending patents. Himalaya has two cab programs currently in phase 2 clinical testing in Taiwan\: BA3011, a novel conditionally active AXL-targeted antibody-drug conjugate (CAB-AXL-ADC), and BA3021, a novel conditionally active ROR2-targeted antibody-drug conjugate (CAB-ROR2-ADC). Himalaya has a co-development and collaboration agreement for an investigational CAB CTLA-4 antibody, BA3071, with BeiGene Ltd. for its development, manufacturing, and commercialization in Greater China. The company was founded by Carolyn Anderson Short and Jay M. Short, and the CEO is Brian Zhang. | - |
| Richard Waldron | M | 70 |
Himalaya Therapeutics
Himalaya Therapeutics Medical/Nursing ServicesHealth Services Himalaya Therapeutics is a Caymanian clinical-stage biotechnology company that is advancing its pipeline of novel monoclonal antibody and other protein therapeutic product candidates through clinical trials. The company is based in George Town, Cayman Islands, with operations in Taiwan and China. The company's product candidates have been developed using cab technology, which is protected by more than 500 issued and pending patents. Himalaya has two cab programs currently in phase 2 clinical testing in Taiwan\: BA3011, a novel conditionally active AXL-targeted antibody-drug conjugate (CAB-AXL-ADC), and BA3021, a novel conditionally active ROR2-targeted antibody-drug conjugate (CAB-ROR2-ADC). Himalaya has a co-development and collaboration agreement for an investigational CAB CTLA-4 antibody, BA3071, with BeiGene Ltd. for its development, manufacturing, and commercialization in Greater China. The company was founded by Carolyn Anderson Short and Jay M. Short, and the CEO is Brian Zhang. | - |
| Wei Guang Lan | M | 60 |
Xiamen University
| 27 Jahre |
| Michael Lyle | M | - |
Welichem Biotech, Inc.
Welichem Biotech, Inc. Pharmaceuticals: MajorHealth Technology Welichem Biotech, Inc. operates as a drug discovery and early stage drug development company focusing on novel therapeutics for autoimmune, inflammatory diseases and cancers. The firm's focus has been on research and development of its novel anti-inflammatory drug candidate, WBI-1001 and its derivatives, and its anticancer drug candidate, WBI-2100 and its derivatives. The company was founded on November 1, 2004 and is headquartered in Burnaby, Canada. | 15 Jahre |
| Scott Smith | M | 61 |
Himalaya Therapeutics
Himalaya Therapeutics Medical/Nursing ServicesHealth Services Himalaya Therapeutics is a Caymanian clinical-stage biotechnology company that is advancing its pipeline of novel monoclonal antibody and other protein therapeutic product candidates through clinical trials. The company is based in George Town, Cayman Islands, with operations in Taiwan and China. The company's product candidates have been developed using cab technology, which is protected by more than 500 issued and pending patents. Himalaya has two cab programs currently in phase 2 clinical testing in Taiwan\: BA3011, a novel conditionally active AXL-targeted antibody-drug conjugate (CAB-AXL-ADC), and BA3021, a novel conditionally active ROR2-targeted antibody-drug conjugate (CAB-ROR2-ADC). Himalaya has a co-development and collaboration agreement for an investigational CAB CTLA-4 antibody, BA3071, with BeiGene Ltd. for its development, manufacturing, and commercialization in Greater China. The company was founded by Carolyn Anderson Short and Jay M. Short, and the CEO is Brian Zhang. | - |
| Jie Fan | M | 50 | 7 Jahre | |
| Zhong Chen | M | 59 |
Xiamen University
| 29 Jahre |
| Brian Zhang | M | - |
Himalaya Therapeutics
Himalaya Therapeutics Medical/Nursing ServicesHealth Services Himalaya Therapeutics is a Caymanian clinical-stage biotechnology company that is advancing its pipeline of novel monoclonal antibody and other protein therapeutic product candidates through clinical trials. The company is based in George Town, Cayman Islands, with operations in Taiwan and China. The company's product candidates have been developed using cab technology, which is protected by more than 500 issued and pending patents. Himalaya has two cab programs currently in phase 2 clinical testing in Taiwan\: BA3011, a novel conditionally active AXL-targeted antibody-drug conjugate (CAB-AXL-ADC), and BA3021, a novel conditionally active ROR2-targeted antibody-drug conjugate (CAB-ROR2-ADC). Himalaya has a co-development and collaboration agreement for an investigational CAB CTLA-4 antibody, BA3071, with BeiGene Ltd. for its development, manufacturing, and commercialization in Greater China. The company was founded by Carolyn Anderson Short and Jay M. Short, and the CEO is Brian Zhang. | - |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Fong Kong Chan | M | 48 | 2 Jahre | |
| Hu Cheng | M | 47 |
Xiamen University
| 11 Jahre |
| Guoqing Li | M | - |
Welichem Biotech, Inc.
Welichem Biotech, Inc. Pharmaceuticals: MajorHealth Technology Welichem Biotech, Inc. operates as a drug discovery and early stage drug development company focusing on novel therapeutics for autoimmune, inflammatory diseases and cancers. The firm's focus has been on research and development of its novel anti-inflammatory drug candidate, WBI-1001 and its derivatives, and its anticancer drug candidate, WBI-2100 and its derivatives. The company was founded on November 1, 2004 and is headquartered in Burnaby, Canada. | 8 Jahre |
| Yong Lei | M | - | 2 Jahre | |
| Guangming Yuan | M | 59 | 1 Jahre | |
| Shu Meng Huang | M | 62 |
Xiamen University
| 5 Jahre |
| Kai Yang | M | 50 |
Baoying Fund Management Co., Ltd.
 Baoying Fund Management Co., Ltd. Investment ManagersFinance Baoying Fund Management Co., Ltd. (BFM) is the asset management subsidiary of State-owned China Railway Trust Co., Ltd. in China. The firm is headquartered in Shenzhen with representative offices in Beijing and Shanghai. Founded in 2001, BFM focuses on local economic development and manages mutual funds. | - |
| Mei Ting Cho | F | 60 | 4 Jahre | |
| Hang Sun | M | 58 |
Xiamen University
| 3 Jahre |
| Guo Zhong Tang | M | 49 |
Xiamen University
| 6 Jahre |
| Xiao Long Li | M | 58 | 1 Jahre | |
| Qing Yuan | M | - |
Xiamen University
| 5 Jahre |
| Xiao Xia Xiao | F | 59 |
Hunan University of Finance & Economics
| 4 Jahre |
| Jie Liu | M | 52 |
Xiamen University
| 5 Jahre |
| Shu Ye | M | 52 |
Xiamen University
| 6 Jahre |
| Yiu Wa Tsui | M | 74 |
Shenzhen Stock Exchange
 Shenzhen Stock Exchange Investment Banks/BrokersFinance Shenzhen Stock Exchange provides real-time trading information, trade monitoring, listing compliance monitoring and general supervision services to exchange members. Its main functions include providing the venue and facilities for securities trading, formulating operational rules, receiving listing applications and arranging securities listing, organizing and supervising securities trading, supervising members; regulating listed companies, managing and disseminating market information and other functions. The company’s products cover equities, mutual funds and bonds. Shenzhen Stock Exchange was founded on December 1, 1990 and is headquartered in Shenzhen, China. | 8 Jahre |
| Chen Li Liu | M | 43 |
Xiamen University
| 7 Jahre |
| Yu Li | M | 51 | 1 Jahre | |
| Hong Tu Yang | M | 49 |
Xiamen University
| 4 Jahre |
| Yan Chen | F | 44 | 1 Jahre | |
| Hai Ou Xu | M | 56 | 2 Jahre | |
| Hai Ping Liu | M | 49 | 6 Jahre | |
| Xiang An Ru | M | 55 | 6 Jahre | |
| Bao Yuan Chen | M | 51 | - | |
| Ding Dong Hu | M | 58 | 7 Jahre | |
| Zhong Lin | M | 55 |
Xiamen University
| 6 Jahre |
| Yi Ming Hu | M | 61 |
Xiamen University
| 4 Jahre |
| Wen Zhou Qu | M | 52 |
Xiamen University
| 6 Jahre |
| Wo Ping Leung | M | 80 | 7 Jahre | |
| Hong Liang Sun | M | 44 |
Xiamen University
| 6 Jahre |
| Harvey S. K. Quan | M | - |
Welichem Biotech, Inc.
Welichem Biotech, Inc. Pharmaceuticals: MajorHealth Technology Welichem Biotech, Inc. operates as a drug discovery and early stage drug development company focusing on novel therapeutics for autoimmune, inflammatory diseases and cancers. The firm's focus has been on research and development of its novel anti-inflammatory drug candidate, WBI-1001 and its derivatives, and its anticancer drug candidate, WBI-2100 and its derivatives. The company was founded on November 1, 2004 and is headquartered in Burnaby, Canada. | - |
| Jane Yue | F | - |
Welichem Biotech, Inc.
Welichem Biotech, Inc. Pharmaceuticals: MajorHealth Technology Welichem Biotech, Inc. operates as a drug discovery and early stage drug development company focusing on novel therapeutics for autoimmune, inflammatory diseases and cancers. The firm's focus has been on research and development of its novel anti-inflammatory drug candidate, WBI-1001 and its derivatives, and its anticancer drug candidate, WBI-2100 and its derivatives. The company was founded on November 1, 2004 and is headquartered in Burnaby, Canada. | 2 Jahre |
| Rong Yi Fang | M | 58 |
Xiamen University
| 5 Jahre |
| Chi Kong Chiu | M | 56 | 1 Jahre | |
| Hoi Ng | M | 50 |
Xiamen University
| 4 Jahre |
| Da Ming Zhang | M | 50 |
Xiamen University
| 3 Jahre |
| Dong Shu | M | 59 |
Xiamen University
| 3 Jahre |
| Wei Ding | M | 51 |
Xiamen University
| 4 Jahre |
| Ming Hung Cheung | M | 60 |
Xiamen University
| 3 Jahre |
| Chao Chen | M | 45 |
Xiamen University
| 4 Jahre |
| Jin Song Lin | M | 48 |
Xiamen University
| 1 Jahre |
| You Zhi Xiang | M | 60 |
Xiamen University
| 3 Jahre |
| Wen Hua Shan | M | 54 |
Xiamen University
| 3 Jahre |
| Yuewu Rong | M | 54 |
Xiamen University
| 6 Jahre |
| Duo Mo Jiang | M | 47 |
Xiamen University
| 4 Jahre |
| Jin Dian Lin | M | 51 |
Xiamen University
| 4 Jahre |
| Yuan Long Liu | M | 50 |
Xiamen University
| 4 Jahre |
| Yan Rong Hong | M | 49 |
Xiamen University
| 4 Jahre |
| Xin Chun Xie | M | 56 |
Xiamen University
| 2 Jahre |
| Yan Huang | F | 46 |
Xiamen University
| 4 Jahre |
| Peng Cui | M | 47 |
Xiamen University
| 4 Jahre |
| Jie Lin | F | 44 |
Xiamen University
| 4 Jahre |
| Bing Luo | M | 46 |
Xiamen University
| 4 Jahre |
| Dong Sheng Huang | M | 49 |
Xiamen University
| 4 Jahre |
| Hoi Fong Tsiang | M | 60 |
Xiamen University
| 4 Jahre |
| Chiu Tung Cheung | M | 49 |
Xiamen University
| 4 Jahre |
| Bei Chen Zhong | M | 49 |
Xiamen University
| 4 Jahre |
| Hao Zeng | M | - |
Xiamen University
| 4 Jahre |
| Yi Yi Dai | M | 57 |
Xiamen University
| 3 Jahre |
| Wei Xiao | M | 59 |
Xiamen University
| 3 Jahre |
| Wen Jin Lin | M | - |
Xiamen University
| 4 Jahre |
| Zi Rong Huang | M | 62 |
Xiamen University
| 2 Jahre |
| Sheng Xiong Lin | M | 59 |
Xiamen University
| 4 Jahre |
| Ming Qu Hong | M | 45 |
Xiamen University
| 4 Jahre |
| Xiao Di You | M | 49 |
Xiamen University
| 4 Jahre |
| De Ren Xie | M | 52 |
Xiamen University
| 3 Jahre |
| Biyun Huang | F | 49 |
Xiamen University
| 4 Jahre |
| Jian Feng Tao | M | 46 |
Xiamen University
| 4 Jahre |
| Pei Qiang Wang | M | 49 |
Xiamen University
| 4 Jahre |
| Ping Xu | M | 61 |
Xiamen University
| 1 Jahre |
| Zhi Liang Yu | M | 55 |
Xiamen University
| 4 Jahre |
| De Ming Zhao | M | 58 |
Xiamen University
| 3 Jahre |
| Yi Long Zeng | M | 53 |
Xiamen University
| 2 Jahre |
| Zhen Zhou | M | 54 |
Xiamen University
| 3 Jahre |
| Zhao Dong Zhang | M | 50 |
Xiamen University
| 4 Jahre |
| Dorothy Wu | F | - |
Xiamen University
| 2 Jahre |
| Yi Ming Wang | M | 47 |
Xiamen University
| 4 Jahre |
| Yu Hui Wu | M | 46 |
Xiamen University
| 4 Jahre |
| Chak Chak Chan | M | 51 |
Xiamen University
| 4 Jahre |
| Rui Huang | F | 62 |
Xiamen University
| 3 Jahre |
| Jian Yu Xie | M | 44 |
Xiamen University
| 4 Jahre |
| Ying Qi He | M | 61 |
Xiamen University
| 3 Jahre |
| Yun Liang Qiu | M | 45 |
Xiamen University
| 4 Jahre |
| Zhong Huang Jian | M | 62 |
Xiamen University
| 3 Jahre |
| Min Lin | M | 46 |
Xiamen University
| 4 Jahre |
| Jin Liang Zhang | M | 55 |
Xiamen University
| 3 Jahre |
| Hui Yu | M | 60 |
Xiamen University
| 1 Jahre |
Statistik
| Land | Beziehungen | % des Gesamten |
|---|---|---|
| China | 72 | 72,00% |
| Cayman Islands | 9 | 9,00% |
| Hong Kong | 8 | 8,00% |
| Bermuda | 7 | 7,00% |
| Kanada | 5 | 5,00% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Xiang Dong Tan
- Persönliches Netzwerk
